Endocannabinoid levels in patients with Parkinson’s disease with and without levodopa-induced dyskinesias

Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson’s Disease and l-DOPA-Induced Dyskinesia

(2019) Nilson Carlos Ferreira Junior et al.   NEUROTOXICITY RESEARCH

Dyskinesia matters

(2019) M. Angela Cenci et al.   MOVEMENT DISORDERS

Recent advances in LC-MS/MS methods to determine endocannabinoids in biological samples: Application in neurodegenerative diseases

(2018) Camila Marchioni et al.   ANALYTICA CHIMICA ACTA

Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson’s disease by metabolomic technology

(2018) Yong Wang et al.   BEHAVIOURAL BRAIN RESEARCH

The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia

(2018) Estefania Rojo-Bustamante et al.   NEUROBIOLOGY OF DISEASE

2-Arachidonoylglycerol: A signaling lipid with manifold actions in the brain

(2018) Marc P. Baggelaar et al.   PROGRESS IN LIPID RESEARCH

Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts

(2018) Alberto J. Espay et al.   ANNALS OF NEUROLOGY

L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey

(2017) S. Perez-Lloret et al.   EUROPEAN JOURNAL OF NEUROLOGY

Endocannabinoid modulation of dopamine neurotransmission

(2017) Dan P. Covey et al.   NEUROPHARMACOLOGY

Parkinson disease

(2017) Werner Poewe et al.   Nature Reviews Disease Primers

Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action

(2016) Maurício dos-Santos-Pereira et al.   NEUROBIOLOGY OF DISEASE

Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia

(2015) Concepción García et al.   BRITISH JOURNAL OF PHARMACOLOGY

Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease

(2015) Ross B. Mounsey et al.   EXPERIMENTAL NEUROLOGY

Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism

(2014) Salvador Sierra et al.   Brain Structure & Function

Control of synaptic function by endocannabinoid-mediated retrograde signaling

(2014) Masanobu KANO   PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES

Genome-wide microarray analysis identifies a potential role for striatal retrograde endocannabinoid signaling in the pathogenesis of experimentall-DOPA-induced dyskinesia

(2014) Yong Wang et al.   SYNAPSE

The Endocannabinoid System and the Brain

(2012) Raphael Mechoulam et al.   Annual Review of Psychology

Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients

(2010) Valerio Pisani et al.   MOVEMENT DISORDERS

Homeostatic changes of the endocannabinoid system in Parkinson's disease

(2010) Valerio Pisani et al.   MOVEMENT DISORDERS

Systematic review of levodopa dose equivalency reporting in Parkinson's disease

(2010) Claire L. Tomlinson et al.   MOVEMENT DISORDERS

In vivo pharmacology of endocannabinoids and their metabolic inhibitors: Therapeutic implications in Parkinson's disease and abuse liability

(2009) Andrea Giuffrida et al.   PROSTAGLANDINS & OTHER LIPID MEDIATORS

The Unified Dyskinesia Rating Scale: Presentation and clinimetric profile

(2008) Christopher G. Goetz et al.   MOVEMENT DISORDERS

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results

(2008) Christopher G. Goetz et al.   MOVEMENT DISORDERS

Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum

(2008) Mauro Maccarrone et al.   NATURE NEUROSCIENCE